Buch
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
Yosef Yarden; Moshe Elkabets (Hrsg.)
160,49
EUR
Lieferzeit 12-13 Tage
Übersicht
Verlag | : | Springer International Publishing |
Buchreihe | : | Resistance to Targeted Anti-Cancer Therapeutics |
Sprache | : | Englisch |
Erschienen | : | 02. 02. 2019 |
Seiten | : | 242 |
Einband | : | Kartoniert |
Höhe | : | 235 mm |
Breite | : | 155 mm |
Gewicht | : | 409 g |
ISBN | : | 9783030098179 |
Sprache | : | Englisch |
Du und »Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways«
Autorinformation
Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.
Inhaltsverzeichnis
Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.